Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

BENCHMARKING A ROBUST, HUMAN-RELEVANT PANCREATIC MICROTISSUE PLATFORM FOR METABOLIC DRUG DISCOVERY AND T2D DISEASE MODELING

Objetivo

Type 2 Diabetes (T2D) affects 537 million adults globally. The T2D drug market exceeds 50 billion USD annually, with GLP-1 receptor agonists as the fastest-growing class. Developing these drugs requires testing compounds on pancreatic beta cells, yet current models fail: rodent islets differ from human islets in architecture and receptor expression, contributing to a 92% clinical failure rate. Donor islets are scarce and variable. Cell lines lack physiological relevance. PancreaScale is a proprietary iPSC-derived platform that generates functional human pancreatic microtissues containing beta, alpha, and delta cells in 15 days using a chemically defined small-molecule protocol. Microtissues self-organize into 3D structures mimicking native islet architecture and demonstrate glucose-stimulated insulin secretion (GSIS). The protocol eliminates recombinant growth factors and animal-derived components, reducing cost of goods by over 90% while ensuring batch consistency from a master iPSC bank.Pan-NAM benchmarks PancreaScale against industrial standards defined by a global leader in metabolic drug development, who specified three validation criteria: (1) reproducible production with CV below 15% and Z-factor above 0.5 in 384-well format, (2) physiological insulin secretion response to GLP-1 agonists benchmarked against human islet data, and (3) a T2D disease model with blunted GSIS and proinsulin-to-insulin ratio above 15%. The 9-month project advances PancreaScale from TRL 4 to TRL 5 through three work packages: industrial scale-up, physiological validation, and T2D disease modeling.
Five Letters of Intent from partners spanning large pharma, contract research organizations, and specialized biotech confirm demand across the drug discovery value chain. The FDA Modernization Act 2.0 and EU Directive 2010/63/EU support adoption of validated human-relevant alternatives for metabolic drug screening.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-EIC - HORIZON EIC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIC-2026-AIC

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

STEMX BIO B.V.
Aportación neta de la UEn
€ 300 000,00
Dirección
GALILEIWEG 8
2333 BD Leiden
Países Bajos
Pyme
Sí
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos